These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 35873301)

  • 1. COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health.
    Richard SA; Epsi NJ; Lindholm DA; Malloy AMW; Maves RC; Berjohn CM; Lalani T; Smith AG; Mody RM; Ganesan A; Huprikar N; Colombo RE; Colombo CJ; Madar C; Jones MU; Larson DT; Ewers EC; Bazan S; Fries AC; Maldonado CJ; Simons MP; Rozman JS; Andronescu L; Mende K; Tribble DR; Agan BK; Burgess TH; Pollett SD; Powers JH;
    Open Forum Infect Dis; 2022 Jul; 9(7):ofac275. PubMed ID: 35873301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) Instrument in Patients With Coronavirus Disease 2019.
    Richard SA; Epsi NJ; Pollett S; Lindholm DA; Malloy AMW; Maves R; Utz GC; Lalani T; Smith AG; Mody RM; Ganesan A; Colombo RE; Colombo CJ; Chi SW; Huprikar N; Larson DT; Bazan S; Madar C; Lanteri C; Rozman JS; English C; Mende K; Tribble DR; Agan BK; Burgess TH; Powers JH;
    Open Forum Infect Dis; 2021 Dec; 8(12):ofab517. PubMed ID: 34901299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor Analysis in Distinguishing Coronavirus Disease 2019 From Other Influenza-like Illness Using a Validated Patient-Reported Outcome Instrument FLU-PRO Plus: A Prospective Real-world Cohort Study.
    Chrenka EA; Roblin DW; Gander JC; Powers JH; Cromwell LX; Kodthala PX; Whiting TS; Sesay MM; Segall MF; Deneal AN; Truitt AR; Sour EU; Martinson BC
    Med Care; 2023 May; 61(5):288-294. PubMed ID: 36917774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic surveillance of patient-reported symptoms of viral respiratory tract infectious Syndromes in diverse populations.
    Gander JC; Chrenka E; Cromwell L; Truitt AR; Sesay M; Segall M; Amouzou SA; Hudgins AF; Kodthala P; Roblin D; Deneal AN; Whiting T; Powers JH; Martinson BC
    BMC Health Serv Res; 2022 Dec; 22(1):1591. PubMed ID: 36581932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing health-related quality of life and identifying disease predictors among patients suspected of having long COVID: an analysis of COMET-ICE clinical trial data.
    Gelhorn HL; Ghafoori P; Cutts K; Birch H; Savva Y; Satram S; Lloyd E; Chen WH
    Front Public Health; 2024; 12():1278106. PubMed ID: 38784592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.
    Sansone NMS; Boschiero MN; Ortega MM; Ribeiro IA; Peixoto AO; Mendes RT; Marson FAL
    Lancet Reg Health Am; 2022 Apr; 8():100177. PubMed ID: 35018359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A machine learning approach identifies distinct early-symptom cluster phenotypes which correlate with hospitalization, failure to return to activities, and prolonged COVID-19 symptoms.
    Epsi NJ; Powers JH; Lindholm DA; Mende K; Malloy A; Ganesan A; Huprikar N; Lalani T; Smith A; Mody RM; Jones MU; Bazan SE; Colombo RE; Colombo CJ; Ewers EC; Larson DT; Berjohn CM; Maldonado CJ; Blair PW; Chenoweth J; Saunders DL; Livezey J; Maves RC; Sanchez Edwards M; Rozman JS; Simons MP; Tribble DR; Agan BK; Burgess TH; Pollett SD;
    PLoS One; 2023; 18(2):e0281272. PubMed ID: 36757946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study.
    Molteni E; Canas LS; Kläser K; Deng J; Bhopal SS; Hughes RC; Chen L; Murray B; Kerfoot E; Antonelli M; Sudre CH; Pujol JC; Polidori L; May A; Hammers PA; Wolf J; Spector PTD; Steves CJ; Ourselin PS; Absoud M; Modat M; Duncan PEL
    Lancet Reg Health Eur; 2022 Aug; 19():100429. PubMed ID: 35821715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study.
    Nygaard U; Holm M; Hartling UB; Glenthøj J; Schmidt LS; Nordly SB; Matthesen AT; von Linstow ML; Espenhain L
    Lancet Child Adolesc Health; 2022 Jul; 6(7):459-465. PubMed ID: 35526537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there any effect of flu vaccine on the SARS-CoV-2 infected patients?
    El-Qutob D; Nieto M; Alvarez-Arroyo L; Carrera-Hueso FJ
    Vacunas; 2022; 23(2):71-76. PubMed ID: 34751212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
    Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
    Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
    Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
    Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI).
    Powers JH; Bacci ED; Leidy NK; Poon JL; Stringer S; Memoli MJ; Han A; Fairchok MP; Coles C; Owens J; Chen WJ; Arnold JC; Danaher PJ; Lalani T; Burgess TH; Millar EV; Ridore M; Hernández A; Rodríguez-Zulueta P; Ortega-Gallegos H; Galindo-Fraga A; Ruiz-Palacios GM; Pett S; Fischer W; Gillor D; Moreno Macias L; DuVal A; Rothman R; Dugas A; Guerrero ML
    PLoS One; 2018; 13(3):e0194180. PubMed ID: 29566007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
    Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
    Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals.
    Jung J; Kim JY; Park H; Park S; Lim JS; Lim SY; Bae S; Lim YJ; Kim EO; Kim J; Park MS; Kim SH
    JAMA Netw Open; 2022 May; 5(5):e2213606. PubMed ID: 35608859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.